Table 3.

Comparison of change from baseline data for placebo and rimonabant groups

Parameter	n	Placebo group mean change ± sd	Rimonabant group mean change ± sd	P value between group mean changes
Body composition parameters
Weight change (kg)	48	−7.4 ± 9.4a	−11.0 ± 4.4a	<0.05
Waist circumference change (cm)	47	−9 ± 8a	−11 ± 7a	0.18
BMI change (kg/m2)	48	−2.5 ± 3.0a	−3.8 ± 1.6a	<0.05
Fat mass change (kg)	48	−4.6 ± 7.4b	−8.3 ± 3.4a	<0.01
% body fat change	48	−1.9 ± 4.5d	−4.5 ± 2.9a	<0.005
FFM change (kg)	48	−3.0 ± 3.8a	−2.3 ± 2.3b	0.51
Visceral fat area change (cm2)	47	−42 ± 52a	−53 ± 30a	0.11
sc fat area change (cm2)	42	−51 ± 66a	−82 ± 52a	<0.05
Deep sc fat area change (cm2)	46	−20 ± 49d	−40 ± 28a	<0.05
FFA and glucose metabolism
IC50(palmitate)f change (pmol/liter)	39	−29 ± 73b	−69 ± 75c	0.21
Glucose slope change (×1000) (mg · kg FFM−1 · min−1/pmol · liter−1)	48	6 ± 12b	9 ± 9a	0.10
IC50(HGO) change (pmol/liter)	47	−4 ± 67	16 ± 89	0.44
IC50(palmitate) change (pmol/liter)	42	−40 ± 68b	−38 ± 23a	0.94
BMR (kcal/24 h)	48	−225 ± 354	−193 ± 266b	0.38
Low insulin rate RER	47	0.045 ± 0.28	0.002 ± 0.11	0.93
High insulin rate RER	48	0.003 ± 0.09	−0.035 ± 0.11	0.23
Serum markers
Adiponectin (μg/ml)	47	3.13 ± 2.83a	3.71 ± 3.05a	0.64
Fibrinogen (g/liter)	47	0.7 ± 0.9a	0.9 ± 0.7a	0.77
Leptin (ng/ml)	47	−13.5 ± 15.0a	−14.0 ± 13.1a	0.57
Apo B (g/liter)	47	−0.1 ± 0.2	0.1 ± 0.3	<0.05
HDL cholesterol (mmol/liter)	47	−0.05 ± 0.20	−0.04 ± 0.2	0.74
LDL cholesterol (mmol/liter)	47	−0.5 ± 0.60a	−0.2 ± 1.0	0.16
Total cholesterol (mmol/liter)	47	−0.8 ± 0.80a	−0.6 ± 1.0d	0.53
Triglycerides (mmol/liter)	47	−0.4 ± 0.5a	−0.7 ± 0.8a	0.22
HbA1c (%)	43	−0.2 ± 0.3b	−0.2 ± 0.2a	0.71

Significance of difference between baseline and end changes within each group is indicated after sd. HDL, High-density lipoprotein; LDL, low-density lipoprotein.

^aP < 0.001.

^bP < 0.005.

^cP < 0.01.

^dP < 0.05.